173 related articles for article (PubMed ID: 38262530)
1. Communication About Chimeric Antigen Receptor T-Cell (CAR-T) Therapy.
Dhawale T; Johnson PC; Boateng K; Barata A; Traeger L; Nelson AM; Lavoie MW; Holmbeck K; Choe J; Nabily A; Tripathi A; Amonoo HL; Frigault M; El-Jawahri A
Transplant Cell Ther; 2024 Apr; 30(4):402.e1-402.e12. PubMed ID: 38262530
[TBL] [Abstract][Full Text] [Related]
2. Prognostic communication about lung cancer in the precision oncology era: A multiple-perspective qualitative study.
Petrillo LA; Shimer SE; Zhou AZ; Sommer RK; Feldman JE; Hsu KE; Greer JA; Traeger LN; Temel JS
Cancer; 2022 Aug; 128(16):3120-3128. PubMed ID: 35731234
[TBL] [Abstract][Full Text] [Related]
3. A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams.
Stenson CL; Vidrine J; Dewhurst F; Osborne W; Menne T; Stocker R
Palliat Med; 2023 Feb; 37(2):215-220. PubMed ID: 36428287
[TBL] [Abstract][Full Text] [Related]
4. A Case Report on the Communication between Oncologists and Physiatrists in the Establishment of Functional Prognosis while Undergoing Chimeric Antigen Receptor T-cell Therapy.
Gupta E; Fu JB; Bruera E
J Med Life; 2020; 13(1):94-97. PubMed ID: 32341708
[TBL] [Abstract][Full Text] [Related]
5. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM; Pennings ERA; Kos M; Mutsaers PGNJ; Lugtenburg PJ; van Meerten T; van Doesum JA; Minnema MC; Jak M; van Dorp S; Vermaat JSP; van der Poel MWM; van Oijen MGH; Kuipers MT; Nijhof IS; Kersten MJ
JCO Oncol Pract; 2023 Mar; 19(3):e407-e416. PubMed ID: 36508702
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology and Predictors of 30-Day Readmission in CAR-T Cell Therapy Recipients.
Sharma A; Singh V; Deol A
Transplant Cell Ther; 2023 Feb; 29(2):108.e1-108.e7. PubMed ID: 36371048
[TBL] [Abstract][Full Text] [Related]
7. Overcoming Barriers to Referral for Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma.
Hoffmann MS; Hunter BD; Cobb PW; Varela JC; Munoz J
Transplant Cell Ther; 2023 Jul; 29(7):440-448. PubMed ID: 37031747
[TBL] [Abstract][Full Text] [Related]
8. Experiences and perspectives on chimeric antigen receptor (CAR) T-cell therapy among recipients, carers and referrers (RE-TELL): a qualitative study to inform CAR T-cell service design.
Fyfe R; Anstis O; Kapadia K; Jordan M; Sword DO; Weinkove R
BMJ Open; 2024 Jan; 14(1):e071112. PubMed ID: 38262637
[TBL] [Abstract][Full Text] [Related]
9. Communication Differences between Oncologists and Palliative Care Clinicians: A Qualitative Analysis of Early, Integrated Palliative Care in Patients with Advanced Cancer.
Thomas TH; Jackson VA; Carlson H; Rinaldi S; Sousa A; Hansen A; Kamdar M; Jacobsen J; Park ER; Pirl WF; Temel JS; Greer JA
J Palliat Med; 2019 Jan; 22(1):41-49. PubMed ID: 30359204
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
11. Late relapse after CAR-T cell therapy for adult patients with hematologic malignancies: A definite evidence from systematic review and meta-analysis on individual data.
Zinzi A; Gaio M; Liguori V; Cagnotta C; Paolino D; Paolisso G; Castaldo G; Nicoletti GF; Rossi F; Capuano A; Rafaniello C
Pharmacol Res; 2023 Apr; 190():106742. PubMed ID: 36963592
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T-Cell Therapy for Hematologic Malignancies: A Practical Review.
Strati P; Gregory T; Majhail NS; Jain N
JCO Oncol Pract; 2023 Sep; 19(9):706-713. PubMed ID: 37406255
[TBL] [Abstract][Full Text] [Related]
13. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
14. Toxicities, intensive care management, and outcome of chimeric antigen receptor T cells in adults: an update.
Bellal M; Malherbe J; Damaj G; Du Cheyron D
Crit Care; 2024 Mar; 28(1):69. PubMed ID: 38444031
[TBL] [Abstract][Full Text] [Related]
15. Beliefs About Advanced Cancer Curability in Older Patients, Their Caregivers, and Oncologists.
Loh KP; Mohile SG; Lund JL; Epstein R; Lei L; Culakova E; McHugh C; Wells M; Gilmore N; Mohamed MR; Kamen C; Aarne V; Conlin A; Bearden J; Onitilo A; Wittink M; Dale W; Hurria A; Duberstein P
Oncologist; 2019 Jun; 24(6):e292-e302. PubMed ID: 31015317
[TBL] [Abstract][Full Text] [Related]
16. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
17. Multi-Stakeholder Qualitative Interviews to Inform Measurement of Patient Reported Outcomes After CAR-T.
Akinola IM; Cusatis R; Pasquini MC; Shaw BE; Bollu V; Dalal A; Tesfaye M; Flynn KE
Transplant Cell Ther; 2023 Apr; 29(4):254.e1-254.e9. PubMed ID: 36634738
[TBL] [Abstract][Full Text] [Related]
18. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
20. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]